Similar Articles for PMID: 24191934

1

Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Ackerman ME, Alter G. Ackerman ME, et al. Curr HIV Res. 2013 Jul;11(5):365-77. doi: 10.2174/1570162x113116660058. Curr HIV Res. 2013. PMID: 24191934 Free PMC article. Review.

Cite

Share

2

Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies.

Lewis GK. Lewis GK. Curr HIV Res. 2013 Jul;11(5):354-64. doi: 10.2174/1570162x113116660060. Curr HIV Res. 2013. PMID: 24191940 Review.

Cite

Share

3

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.

Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME. Brown EP, et al. J Immunol Methods. 2017 Apr;443:33-44. doi: 10.1016/j.jim.2017.01.010. Epub 2017 Feb 3. J Immunol Methods. 2017. PMID: 28163018 Free PMC article.

Cite

Share

4

Editorial: Fc receptor-mediated effector functions in the humoral control of HIV-1 infection.

DeVico A. DeVico A. Curr HIV Res. 2013 Jul;11(5):343-4. doi: 10.2174/1570162x113116660056. Curr HIV Res. 2013. PMID: 24191941 No abstract available.

Cite

Share

5

HIV-specific antibody immunity mediated through NK cells and monocytes.

Kramski M, Parsons MS, Stratov I, Kent SJ. Kramski M, et al. Curr HIV Res. 2013 Jul;11(5):388-406. doi: 10.2174/1570162x113116660061. Curr HIV Res. 2013. PMID: 24191935 Review.

Cite

Share

6

HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.

Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, Abdool Karim S, Moore PL, Ackerman ME, Alter G, Morris L. Richardson SI, et al. PLoS Pathog. 2018 Apr 9;14(4):e1006987. doi: 10.1371/journal.ppat.1006987. eCollection 2018 Apr. PLoS Pathog. 2018. PMID: 29630668 Free PMC article.

Cite

Share

7

Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Vargas-Inchaustegui DA, Robert-Guroff M. Vargas-Inchaustegui DA, et al. Curr HIV Res. 2013 Jul;11(5):407-20. doi: 10.2174/1570162x113116660063. Curr HIV Res. 2013. PMID: 24191937 Free PMC article.

Cite

Share

8

Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination.

Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, Streeck H, Pau M, Schuitemaker H, Francis D, Fast P, Laufer D, Walker BD, Baden L, Barouch DH, Alter G. Mahan AE, et al. PLoS Pathog. 2016 Mar 16;12(3):e1005456. doi: 10.1371/journal.ppat.1005456. eCollection 2016 Mar. PLoS Pathog. 2016. PMID: 26982805 Free PMC article.

Cite

Share

9

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Excler JL, et al. Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Clin Vaccine Immunol. 2014. PMID: 24920599 Free PMC article. Review.

Cite

Share

10

An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.

Shubin Z, Li W, Poonia B, Ferrari G, LaBranche C, Montefiori D, Zhu X, Pauza CD. Shubin Z, et al. Clin Vaccine Immunol. 2017 Jun 5;24(6):e00028-17. doi: 10.1128/CVI.00028-17. Print 2017 Jun. Clin Vaccine Immunol. 2017. PMID: 28404572 Free PMC article.

Cite

Share